We need Leveraged products to multiply wealth faster and safer. The notion that leveraged products are unsafe is just not true. They are very easy to use unlike options which are far more leveraged and complex to use. I and many of my friends have been using 2X and 3X ETF / ETN products well over a decade and these products have helped make a positive impact on our investment portfolios. Taking these products off the market or making them hard to access is not a great idea for retail investors like us. I plead to you authorities to please NOT make any changes to the availability of these products in the free market. Non-availability of these products will make our portfolios show overall smaller gains. Thank you for your consideration.
For the Public
FINRA DATA
FINRA Data provides non-commercial use of data, specifically the ability to save data views and create and manage a Bond Watchlist.
For Industry Professionals
FINPRO
Registered representatives can fulfill Continuing Education requirements, view their industry CRD record and perform other compliance tasks.
For Member Firms
FINRA GATEWAY
Firm compliance professionals can access filings and requests, run reports and submit support tickets.
For Case Participants
DR PORTAL
Arbitration and mediation case participants and FINRA neutrals can view case information and submit documents through this Dispute Resolution Portal.
Need Help? | Check System Status
Log In to other FINRA systems
Rajesh Patil Comment On Regulatory Notice 22-08
We need Leveraged products to multiply wealth faster and safer. The notion that leveraged products are unsafe is just not true. They are very easy to use unlike options which are far more leveraged and complex to use. I and many of my friends have been using 2X and 3X ETF / ETN products well over a decade and these products have helped make a positive impact on our investment portfolios. Taking these products off the market or making them hard to access is not a great idea for retail investors like us. I plead to you authorities to please NOT make any changes to the availability of these products in the free market. Non-availability of these products will make our portfolios show overall smaller gains. Thank you for your consideration.